CU20170094A7 - Derivados de 4h-pirrol[3,2-c]piridin-4-0na - Google Patents

Derivados de 4h-pirrol[3,2-c]piridin-4-0na

Info

Publication number
CU20170094A7
CU20170094A7 CUP2017000094A CU20170094A CU20170094A7 CU 20170094 A7 CU20170094 A7 CU 20170094A7 CU P2017000094 A CUP2017000094 A CU P2017000094A CU 20170094 A CU20170094 A CU 20170094A CU 20170094 A7 CU20170094 A7 CU 20170094A7
Authority
CU
Cuba
Prior art keywords
compounds
diseases
pirrol
piridin
derivatives
Prior art date
Application number
CUP2017000094A
Other languages
English (en)
Inventor
Dr József Bálint
Dr Hans Briem
Dr Keith Graham
Dr Ulrich Klar
Dr Philip Lienau
Dr Volker Schulze
Dr Gerhard Siemeister
René Tempel
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20170094A7 publication Critical patent/CU20170094A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a compuestos de 4H-pirrol[3,2-c]piridin-4-ona sustituidos que son los inhibidores de Bub1 y resultan útiles para el tratamiento de los trastornos proliferativos asociados con un aumento de los procesos celulares proliferativos descontrolados tales como, por ejemplo, cáncer, inflamación, artritis, enfermedades virales, enfermedades cardiovasculares o enfermedades fúngicas en un animal de sangre caliente tal como el hombre.</p> <p>Dichos compuestos se caracterizan por la fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>En donde: R1,  R2,  R3,  RA, RB, A y E tiene los significados dados en las reivindicaciones.</p>
CUP2017000094A 2015-01-28 2016-01-25 Derivados de 4h-pirrol[3,2-c]piridin-4-0na CU20170094A7 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15152944 2015-01-28
EP15200407 2015-12-16
PCT/EP2016/051432 WO2016120196A1 (en) 2015-01-28 2016-01-25 4h-pyrrolo[3,2-c]pyridin-4-one derivatives

Publications (1)

Publication Number Publication Date
CU20170094A7 true CU20170094A7 (es) 2017-12-08

Family

ID=55236350

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2017000094A CU20170094A7 (es) 2015-01-28 2016-01-25 Derivados de 4h-pirrol[3,2-c]piridin-4-0na

Country Status (30)

Country Link
US (1) US10428063B2 (es)
EP (1) EP3250567B1 (es)
JP (1) JP6704398B2 (es)
KR (1) KR102544847B1 (es)
CN (1) CN107406417B (es)
AU (1) AU2016212230B2 (es)
BR (1) BR112017016193B1 (es)
CA (1) CA2974853C (es)
CL (1) CL2017001930A1 (es)
CO (1) CO2017007663A2 (es)
CR (1) CR20170345A (es)
CU (1) CU20170094A7 (es)
DO (1) DOP2017000176A (es)
EA (1) EA032530B1 (es)
EC (1) ECSP17048527A (es)
IL (1) IL253284B (es)
JO (1) JO3706B1 (es)
MX (1) MX380239B (es)
MY (1) MY182181A (es)
NI (1) NI201700096A (es)
PE (1) PE20171240A1 (es)
PH (1) PH12017501340A1 (es)
SG (1) SG11201705908VA (es)
SV (1) SV2017005487A (es)
TN (1) TN2017000329A1 (es)
TW (1) TWI699359B (es)
UA (1) UA122221C2 (es)
UY (1) UY36544A (es)
WO (1) WO2016120196A1 (es)
ZA (1) ZA201705802B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157914B1 (en) 2014-06-17 2018-09-26 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107922389A (zh) 2015-06-17 2018-04-17 拜耳制药股份公司 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
US10308629B2 (en) 2015-08-05 2019-06-04 Bayer Pharma Aktiengesellschaft 1H-pyrrol-3-amines
CN114716381B (zh) 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
WO2018158175A1 (en) 2017-02-28 2018-09-07 Bayer Pharma Aktiengesellschaft Combination of bub1 inhibitors
WO2018206547A1 (en) 2017-05-12 2018-11-15 Bayer Pharma Aktiengesellschaft Combination of bub1 and atr inhibitors
WO2018215282A1 (en) 2017-05-26 2018-11-29 Bayer Pharma Aktiengesellschaft Combination of bub1 and pi3k inhibitors
KR102440006B1 (ko) 2017-08-23 2022-09-05 현대모비스 주식회사 차량용 브레이크의 캘리퍼 장치
EP3700904B1 (en) 2017-10-24 2023-07-19 Bayer AG 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
EP3921317B1 (en) 2019-02-07 2023-08-02 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
US20240307362A1 (en) 2019-04-24 2024-09-19 Bayer Aktiengesellschaft 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS
DK3959211T3 (da) * 2019-04-24 2026-04-27 Bayer Ag 4h-pyrrol[3,2-c]pyridin-4-on-forbindelser
US12403135B2 (en) * 2019-04-24 2025-09-02 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2022023340A1 (en) 2020-07-29 2022-02-03 Bayer Aktiengesellschaft Substituted heterocyclic compounds and therapeutic uses thereof
US20230322767A1 (en) 2020-07-29 2023-10-12 Bayer Aktiengesellschaft Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof
US20230365554A1 (en) 2020-07-29 2023-11-16 The Broad Institute, Inc. Substituted pyrrolo-pyridinone derivatives and therapeutic uses thereof
EP4188928B1 (en) 2020-07-29 2024-07-24 Bayer Aktiengesellschaft Substituted 1 h-pyrrolo[3,2-b]pyridin compounds and methods of use thereof
CN115836070B (zh) * 2020-08-10 2024-08-09 上海和誉生物医药科技有限公司 作为egfr抑制剂的稠环化合物及其制备方法和应用
KR20230094197A (ko) 2020-09-23 2023-06-27 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료에 유용한 피롤로[3,2-c]피리딘-4-온 유도체들
CN116997549A (zh) * 2020-09-23 2023-11-03 蝎子疗法股份有限公司 用于治疗癌症的吡咯并[3,2-c]吡啶-4-酮衍生物
WO2022072645A2 (en) * 2020-09-30 2022-04-07 Scorpion Therapeutics, Inc. Methods for treating cancer
KR20230107419A (ko) * 2020-10-09 2023-07-14 스코르피온 테라퓨틱스, 인코퍼레이티드 암 치료 방법
CN116981667A (zh) * 2020-10-09 2023-10-31 蝎子疗法股份有限公司 用于癌症治疗的egfr和/或her2的杂环抑制剂
WO2022094271A1 (en) * 2020-10-30 2022-05-05 Scorpion Therapeutics, Inc. Methods for treating cancer
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
EP4469457A4 (en) * 2022-01-27 2026-01-21 Broad Inst Inc CSNK1 SUBSTITUTE HETEROCYCLIC INHIBITORS
CA3246654A1 (en) 2022-03-24 2023-09-28 Antares Therapeutics, Inc. METHODS FOR SYNTHESIZING EGFR INHIBITORS
WO2024182715A1 (en) * 2023-03-02 2024-09-06 Schrödinger, Inc. Heterocyclics as egfr inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
WO2009040399A1 (en) 2007-09-28 2009-04-02 Nerviano Medical Sciences S.R.L. Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors
DK2294065T3 (da) * 2008-01-22 2014-04-28 Vernalis R&D Ltd Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet
US8546413B2 (en) * 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
UA111754C2 (uk) 2011-10-06 2016-06-10 Байєр Фарма Акцієнгезелльшафт Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань
JP6063945B2 (ja) * 2011-10-07 2017-01-18 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害剤としての４−アルキル置換３，４−ジヒドロピロロ［１，２−ａ］ピラジン−１（２Ｈ）−オン誘導体
CN103906732A (zh) 2011-10-28 2014-07-02 株式会社钟根堂 用作hdac抑制剂的异羟肟酸酯衍生物以及包含所述衍生物的药物组合物
ES2638144T3 (es) 2011-12-21 2017-10-18 Bayer Intellectual Property Gmbh Bencilpirazoles sustituidos
ES2620316T3 (es) 2012-05-11 2017-06-28 Bayer Pharma Aktiengesellschaft Cicloalquenopirazoles sustituidos como inhibidores de BUB1 para el tratamiento del cáncer
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
ES2755772T3 (es) 2012-11-07 2020-04-23 Nerviano Medical Sciences Srl Pirimidinil y piridinilpirrolopiridinonas sustituidas, proceso para su preparación y su uso como inhibidores de cinasas
WO2014147204A1 (en) 2013-03-21 2014-09-25 Bayer Pharma Aktiengesellschaft Heteroaryl substituted indazoles
HK1218750A1 (zh) * 2013-03-21 2017-03-10 Bayer Pharma Aktiengesellschaft 3-杂芳基取代的吲唑
ES2652305T3 (es) 2013-06-21 2018-02-01 Bayer Pharma Aktiengesellschaft Pirazoles heteroaril sustituidos
US9765058B2 (en) 2013-06-21 2017-09-19 Bayer Pharma Aktiengesellschaft Substituted benzylpyrazoles
HK1222846A1 (zh) 2013-06-21 2017-07-14 Bayer Pharma Aktiengesellschaft 取代的苄基吡唑
HK1223097A1 (zh) 2013-06-21 2017-07-21 Bayer Pharma Aktiengesellschaft 杂芳基取代的吡唑
EP3033342A1 (en) 2013-08-13 2016-06-22 Grünenthal GmbH Annelated pyrroles and their use as crac inhibitors
EP3157914B1 (en) * 2014-06-17 2018-09-26 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
CN107922389A (zh) 2015-06-17 2018-04-17 拜耳制药股份公司 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮
US10308629B2 (en) 2015-08-05 2019-06-04 Bayer Pharma Aktiengesellschaft 1H-pyrrol-3-amines
US20200216439A1 (en) 2015-12-16 2020-07-09 Bayer Pharma Aktiengesellschaft Hetero-1,5,6,7-tetrahydro-4h-indol-4-ones

Also Published As

Publication number Publication date
EA201791692A1 (ru) 2018-01-31
BR112017016193B1 (pt) 2023-02-23
TN2017000329A1 (en) 2019-01-16
MX2017009831A (es) 2017-11-02
EA032530B1 (ru) 2019-06-28
AU2016212230A1 (en) 2017-07-20
AU2016212230B2 (en) 2019-09-19
CN107406417B (zh) 2020-06-09
ZA201705802B (en) 2019-07-31
IL253284A0 (en) 2017-09-28
CR20170345A (es) 2017-09-29
CA2974853A1 (en) 2016-08-04
SG11201705908VA (en) 2017-08-30
JO3706B1 (ar) 2021-01-31
NI201700096A (es) 2017-10-24
TW201639828A (zh) 2016-11-16
US20180016272A1 (en) 2018-01-18
SV2017005487A (es) 2019-01-17
KR20170106452A (ko) 2017-09-20
MX380239B (es) 2025-03-12
BR112017016193A2 (pt) 2018-04-17
CN107406417A (zh) 2017-11-28
US10428063B2 (en) 2019-10-01
PE20171240A1 (es) 2017-08-24
DOP2017000176A (es) 2017-08-31
KR102544847B1 (ko) 2023-06-16
HK1244804A1 (zh) 2018-08-17
UA122221C2 (uk) 2020-10-12
TWI699359B (zh) 2020-07-21
CA2974853C (en) 2023-02-21
EP3250567B1 (en) 2019-10-30
PH12017501340A1 (en) 2017-12-18
WO2016120196A1 (en) 2016-08-04
UY36544A (es) 2016-08-31
JP6704398B2 (ja) 2020-06-03
IL253284B (en) 2020-08-31
JP2018503648A (ja) 2018-02-08
EP3250567A1 (en) 2017-12-06
CO2017007663A2 (es) 2017-10-10
CL2017001930A1 (es) 2018-03-09
ECSP17048527A (es) 2017-10-31
MY182181A (en) 2021-01-18

Similar Documents

Publication Publication Date Title
CU20170094A7 (es) Derivados de 4h-pirrol[3,2-c]piridin-4-0na
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
PH12018500718A1 (en) Compounds useful as modulators of trpm8
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
MX377552B (es) Proceso para preparar un compuesto antiviral de formula i.
CU24410B1 (es) Benzimidazol-2-aminas como inhibidores de midh1
CO2017001884A2 (es) Polimorfos de selinexor
MX2015012427A (es) Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer.
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
BR112016023558A2 (pt) compostos úteis como imunomoduladores
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
MX2018001032A (es) Compuestos utiles para el tratamiento de trastornos relacionados con kit y pdgfr.
EA201692114A1 (ru) Замещенные дигидроизохинолиноновые соединения
UY36702A (es) Piridinas sustituidas y métodos de uso
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
ECSP17010482A (es) Novedosas pirimidinas 2,5-sustituidas
DOP2016000211A (es) Pirazinas moduladoras de gpr6